|
Harbin Jixianglong Biotech Co., Ltd.
|
Eptifibatide CAS No.: 188627-80-7
Peptide Sequence:
Mpa-Har-Gly-Asp-Trp-Pro-Cys-NH2(Disulfide bridge: Mpa1-Cys6)
Eptifibatide is a platelet glycoprotein IIb/IIIa receptor reversible antagonist. It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction. It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events.
| Product Name |
Eptifibatide |
| CAS NO. |
188627-80-7 |
| Appearance |
White Powder |
| Purity |
99% or customized |
| Application |
Drug peptides |
| Usage |
Eptifibatide is a platelet glycoprotein IIb/IIIa receptor reversible antagonist. |
Related Products
| Name |
CAS No. |
Name |
CAS No. |
| Eptifibatide |
188627-80-7 |
Thymalfasin |
69440-99-9 |
| Terlipressin Acetate |
14636-12-5 |
Thymopentin Acetate (TP-5) |
69558-55-0 |
| Astosiban Acetate |
90779-69-4 |
Octreotide Acetate |
83150-76-9 |
| Liraglutide |
204656-20-2 |
Melanotan II Acetate |
121062-08-6 |
| Teriparatide |
52232-67-4 |
Melanotan I Acetate |
75921-69-6 |
| Bivalirudin |
128270-60-0 |
Secretin Acetate |
17034-35-4 |
| Carbetocin |
37025-55-1 |
Ornipressin Acetate |
3397-23-7 |
| Thymosin Beta 4 |
77591-33-4 |
Oxytocin Acetate |
50-56-6 |
| Calcitonin |
60731-46-6 |
Lypressin Acetate |
50-57-7 |
| Semaglutide |
910463-68-2 |
Argpressin Acetate |
113-79-1 |
| Abaloparatide |
247062-33-5 |
Calcitonin (Salmone) Acetate |
47931-85-1 |
  Company Profile
Founded in 2011, Harbin Jixianglong Biotech Co., Ltd. is a is a professional high-tech company specializing in R&D and production of polypeptide pharmaceuticals. Our advanced industry chain occupied in R&D, approbation and industrialization of peptides API and preparation.
Jixianglong has peptide drug production workshop and pilot workshop for personalized cancer neoantigen peptide vaccine which approved by GMP standard. More than 300 sets advanced instruments for production and testing, such as Solid phase synthesizer, Preparative liquid chromatograph, Freeze dryer, High performance liquid chromatograph etc.
Main Products:
10 items completed polypeptide API declared:
Eptifibatide, Somatostatin, Terlipressin Acetate, Thymalfasin, Atosiban Acetate, Carbetocin, Oxytocin, Ganirelix Acetate, Octreotide Acetate, Cetrorelix Acetate.
N items as researching reserve series:
Teriparatide, Bivalirudin, Liraglutide, Nesiritide, Abaloparatide, Semaglutide, Personalized cancer neoantigen peptide vaccine, Peptide drug conjugate (PDC).
|
Send Inquiry
|
|
Suzhou Pharmaserve Technology Co., Ltd.
|
Eptifibatide Pharmaserve is a peptide-based antagonist for glycoprotein IIb/IIIa used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention.
Eptifibatide Pharmaserve is a glycoprotein IIb/IIIa class platelet inhibitor drug used to reduce ischemic cardiac events in specific patient populations.
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.
|
Send Inquiry
|
Pharma Sources Insight January 2025
